Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies

Limited response rates and frequent relapses during standard of care with hypomethylating agents in myelodysplastic neoplasms (MN) require urgent improvement of this treatment indication. Here, by combining 5-azacytidine (5-AZA) with the pan-lysyl oxidase inhibitor PXS-5505, we demonstrate superior...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qingyu, Streuer, Alexander, Jann, Johann-Christoph, Altrock, Eva, Schmitt, Nanni, Flach, Johanna, Sens-Albert, Carla, Rapp, Felicitas, Wolf, Julia, Nowak, Verena, Weimer, Nadine, Obländer, Julia, Palme, Iris, Kuzina, Mariia, Jawhar, Ahmed, Darwich, Ali, Weis, Cleo-Aron, Marx, Alexander, Wuchter, Patrick, Costina, Victor, Jäger, Evelyn, Sperk, Elena, Neumaier, Michael, Fabarius, Alice, Metzgeroth, Georgia, Nolte, Florian, Steiner, Laurenz, Levkin, Pavel A., Jawhar, Mohamad, Hofmann, Wolf-Karsten, Riabov, Vladimir, Nowak, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023686/
https://www.ncbi.nlm.nih.gov/pubmed/36932114
http://dx.doi.org/10.1038/s41467-023-37175-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023686/
https://www.ncbi.nlm.nih.gov/pubmed/36932114
http://dx.doi.org/10.1038/s41467-023-37175-8

Ejemplares similares